---
title: 'Prognostic factors for overall survival in castration-resistant metastatic
  prostate cancer treated with docetaxel (MeProCSS): results from a German real-world
  cohort'
date: '2025-01-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39871032/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250128170841&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: MeProCSS, consisting of routinely collected parameters prior
  to the start of chemotherapy, seems to effectively stratify patients with mCRPC
  into risk groups based on their metastatic burden, nutritional and inflammatory
  status. This model may guide treatment decisions and reveal a potentially often
  underestimated or overlooked urgency for additional measures as supportive palliative
  care in mCRPC patients. Further large and prospective studies are necessary for
  validation ...'
disable_comments: true
---
CONCLUSION: MeProCSS, consisting of routinely collected parameters prior to the start of chemotherapy, seems to effectively stratify patients with mCRPC into risk groups based on their metastatic burden, nutritional and inflammatory status. This model may guide treatment decisions and reveal a potentially often underestimated or overlooked urgency for additional measures as supportive palliative care in mCRPC patients. Further large and prospective studies are necessary for validation ...